The global attention deficit hyperactivity disorder drugs market is expected to grow at a CAGR of 5.59% during the forecast period. Based on the product, the market has been segmented into stimulants and non-stimulants. As per the latest market research report published by Technavio, the global attention deficit hyperactivity disorder drugs market size will grow at a CAGR of almost 6% during 2018-2023. Get the free sample report below for the detailed information.

 Download the free sample report @ http://bit.ly/3549v7p

Stimulants are considered as the first-line therapy for the treatment of ADHD. Hypothetically it seems contradictory to treat ADHD symptoms with CNS stimulant or psychostimulant, it works by increasing neurotransmitter levels in the brain, namely dopamine and norepinephrine, which play an important role in improving brain functions. The therapeutic efficacy for the treatment of ADHD has been established for over 50 years, and they are the most popular prescribed medication for the treatment. 

Stimulants are approved by the US FDA for use in children and adults and are considered as gold standards for the treatment of ADHD. As per the NIH, in 2008, approximately 2.8 million children with ADHD were reported to be receiving psychostimulants for their treatment. Additionally, there are more than 250 controlled studies that have demonstrated the therapeutic efficacy of stimulants for the treatment of ADHD. Considering the vast use of stimulants in the ADHD therapeutic area, the attention deficit hyperactivity disorder drugs market is expected to witness rapid growth during the forecast period. To know the complete and in-depth analysis and forecast of this market get the complete report by clicking the link below.

Get the Complete Report @ http://bit.ly/2qfA2jh